Live Breaking News & Updates on Med Private Investments

Stay updated with breaking news from Med private investments. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Week In Review: Hansoh Sells Ex-China ADC Rights To GSK In $1.6 Billion Deal

Week In Review: Hansoh Sells Ex-China ADC Rights To GSK In $1.6 Billion Deal
seekingalpha.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from seekingalpha.com Daily Mail and Mail on Sunday newspapers.

New York , United States , North Lanarkshire , United Kingdom , Hong Kong , Woodland Hills , San Diego , City Of , New Zealand , San Francisco , Hansoh Pharma , Orbimed Asia , Ocean Bio , Sichuan Kelun , Francisco Aiolos Bio , Intas Pharmaceuticals , Morningside Group , Translational Center , Research Center , H Health Investment , Oriza Holdings , Med Private Investments , Orbimed Royalty , Bristol Myers Squibb , Aiolos Bio , Jiangsu Hengrui Medicine ,

Kinnate Biopharma Inc. Closes $35 Million Series A Financing to Establish a Chinese Joint Venture

Kinnate Biopharma Inc. Closes $35 Million Series A Financing to Establish a Chinese Joint Venture
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United States , Hong Kong , San Diego , San Francisco , Kinnate Biopharma , Nima Farzan , Stevend Wang , Wenn Sun , Patti Bankwestwicke , Lurie Cancer Center , Exchange Commission , University Of Wisconsin , Partner For Oxonc Development , Kinnate Biopharma Inc , Northwestern University , Business Development , National Comprehensive Cancer Network , Orbimed Asia Partners , Orbimed Private Investments , Foresite Capital , Greater China , Med Private Investments , Rapidly Accelerated Fibrosarcoma , Fibroblast Growth Factor Receptors , Senior Managing Director , Orbimed Asia ,

Kinnate Biopharma Inc. Closes $35 Million Series A

Kinnate Biopharma Inc. Closes $35 Million Series A Financing to Establish a Chinese Joint Venture
May 13, 2021 16:02 ET
| Source:
Kinnate Biopharma
Kinnate Biopharma
Financing led by OrbiMed Asia Partners, with participation from OrbiMed Private Investments and Foresite Capital
The joint venture will have exclusive license to develop and commercialize Kinnate’s currently most advanced kinase inhibitor candidates in Greater China
Veteran biopharmaceutical industry executive Wenn Sun, Ph.D. has been named as Executive Chair
SAN FRANCISCO and SAN DIEGO, May 13, 2021 (GLOBE NEWSWIRE) Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers, announced the closing of a $35 million Series A financing for a joint venture in China. Established with OrbiMed Asia Partners, O ....

United States , Hong Kong , San Diego , San Francisco , Colin Sanford , Kinnate Biopharma , Nima Farzan , Stevend Wang , Wenn Sun , Patti Bank , Lurie Cancer Center , Exchange Commission , University Of Wisconsin , Partner For Oxonc Development , Kinnate Biopharma Inc , Northwestern University , Business Development , National Comprehensive Cancer Network , Orbimed Asia Partners , Orbimed Private Investments , Foresite Capital , Greater China , Med Private Investments , Rapidly Accelerated Fibrosarcoma , Fibroblast Growth Factor Receptors , Senior Managing Director ,